Parameter
| Biomarker | IL-10/IL-6 ratio | Full name | interleukin-10/interleukin-6 ratio | Molecular Type | Protein composition |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis | ||
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Serum, cerebrospinal fluid (cellular microbead array) | ||
| Pathobiological Mechanisms | A ratio ≥2.30 predicts SCNSL risk and adverse PFS | ||||
| Clinical Availability Status | Validation phase of the study: 56 patients were validated, requiring multicenter and alternative sample testing for exploration. | ||||
| Notes and Dynamics | Validation of multicenter value and exploration of serum as a potential alternative to cerebrospinal fluid testing. | ||||